Haematologie-Onkologie im Zentrum MVZ GmbH — Clinical Trial Site

36 Registered trials

19 Currently recruiting

Organisation

Haematologie-Onkologie im Zentrum MVZ GmbH

Location

Augsburg, Germany

Identifier

ORG-100049016

Address

Halderstrasse 29, Innenstadt, 86150, Germany

Departments

-
#1605: Private Practice
#3131: Haematologie-Onkologie im Zentrum MVZ GmbH
049017: Haemato., Onko., Med. Tumorthe
Dres. Heinrich / Bangerter
Fachärzte für Innere Medizin, Hämatologie und Onkologie
Haematologie
Haematologie-Onkologie im Zentrum
Haematologie-Onkologie im Zentrum MVZ GmbH
Hämatologie-Onkologie
Hämatologie-Onkologie im Zentrum MVZ
Hämatologie-Onkologie Im Zentrum MVZ GmbH
Hämatologisch-onkologische Gemeinschaftspraxis
Hematology- Oncology
Innere Medizin, Hämatologie, Onkologie und Medikamentöse Tumortherapie
Intern. Onkologie/Haematologie
Klinik fuer Haematologie, Onkologie und Immunologie
N/A
NA
Oncology
Praxis
Praxis Drs. Heinrich/Bangerter

Clinical trials at this site (36)

Search interface

Combination of Abemaciclib and endocrine therapy in hormone receptor positive HER2 negative locally advanced or metastatic breast cancer wit… Ended

2024-511209-49-00 Patients with hormone receptor positive HER2 negative l 6 2022-04-26
A clinical study to assess the efficacy of alpelisib plus fulvestrant in participants with HR-positive, HER2-negative, advanced breast cance… Ended

2023-509133-39-00 Hormone receptor positive, HER2-negative advanced breas 5 2021-11-29
Phase Ib/III Study of Capivasertib + CDK4/6 Inhibitors + Fulvestrant as Treatment for Advanced/Metastatic HR+/HER2-Breast Cancer (CAPItello-… Ended

2023-504997-39-00 Hormone Receptor-Positive and Human Epidermal Growth Fa 5 2021-06-14
Clinical trial comparing Trastuzumab Deruxtecan with Trastuzumab Emtansine in high-risk HER2-positive patients with residual breast cancer f… Ended

2023-507961-24-00 High-Risk HER2-Positive Breast Cancer 5 2021-04-19
Sacituzumab Govitecan in primary HER2-negative breast cancer (SASCIA) Ended

2023-510390-33-00 HER2-negative breast cancer patients with high relapse 5 2020-10-23
A randomized, controlled, open-label, phase III-trial on Adjuvant Dynamic marker - Adjusted Personalized Therapy comparing abemaciclib combi… Ended

2023-509242-35-00 HR+/HER2- early breast cancer 5 2020-07-23
A phase III multi-center, randomized, open-label trial to evaluate efficacy and safety of ribociclib with endocrine therapy as adjuvant trea… Ended

2023-510357-42-00 hormone receptor (HR)-positive, HER2-negative, early br 5 2019-05-22
Endocrine Therapy With or Without Abemaciclib (LY2835219) Following Surgery in Participants With Breast Cancer (monarchE) Ended

2023-509671-17-00 Breast Cancer 5 2017-07-12
Olaparib as adjuvant treatment in patients with germline BRCA mutated high risk HER2negative primary breast cancer. Ended

2024-511096-15-00 Breast Cancer 5 2014-08-01
HU-F-AIM - A prospective, interventional clinical study to evaluate hydroxyurea (HU) resistance in patients with polycythaemia vera who meet… Ended

2022-502338-20-00 Polycythemia vera 6 2023-07-28
A Randomized, Double-Blind, Phase III Clinical Trial of Neoadjuvant Chemotherapy with Atezolizumab or Placebo in Patients with Triple-Negati… Ended

2023-508472-11-00 Patients with early breast cancer 5 2018-06-13
HD21 Ended

2024-518022-33-00 Advanced Stage of Hodgkin Lymphoma 5 2016-07-15